A number of other analysts have also recently weighed in on OSUR. Canaccord Genuity restated a hold rating and issued a $7.00 price target on shares of OraSure Technologies in a research note on Wednesday, August 14th. Zacks Investment Research cut OraSure Technologies from a hold rating to a sell rating in a research note on Tuesday, July 9th. Three research analysts have rated the stock with a sell rating and one has issued a hold rating to the company’s stock. The company presently has an average rating of Sell and a consensus target price of $7.00.
OraSure Technologies stock opened at $7.59 on Thursday. OraSure Technologies has a 1-year low of $6.35 and a 1-year high of $16.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.99 and a quick ratio of 6.13. The stock has a market cap of $468.80 million, a PE ratio of 15.18, a P/E/G ratio of 1.64 and a beta of 1.27. The stock’s fifty day moving average is $7.40 and its two-hundred day moving average is $9.05.
OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.04. OraSure Technologies had a return on equity of 7.81% and a net margin of 11.83%. The company had revenue of $38.83 million for the quarter, compared to analysts’ expectations of $41.48 million. During the same period last year, the firm earned $0.07 earnings per share. OraSure Technologies’s quarterly revenue was down 11.0% on a year-over-year basis. On average, research analysts expect that OraSure Technologies will post 0.37 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. Roble Belko & Company Inc acquired a new stake in OraSure Technologies in the first quarter valued at $29,000. Acadian Asset Management LLC purchased a new position in shares of OraSure Technologies during the second quarter worth about $25,000. Parallel Advisors LLC purchased a new position in shares of OraSure Technologies during the first quarter worth about $33,000. BSW Wealth Partners purchased a new position in shares of OraSure Technologies during the second quarter worth about $29,000. Finally, Panagora Asset Management Inc. grew its holdings in shares of OraSure Technologies by 34.3% during the second quarter. Panagora Asset Management Inc. now owns 9,851 shares of the medical instruments supplier’s stock worth $91,000 after purchasing an additional 2,514 shares during the last quarter. Institutional investors own 94.21% of the company’s stock.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Further Reading: Why does a company issue an IPO?
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.